Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. - Wikidata - awgldk - TriplyDB

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.

http://www.wikidata.org/entity/Q35924939

about

The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release The σ2 receptor: a novel protein for the imaging and treatment of cancer.Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery.Early development of sigma-receptor ligands.Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site.Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.Characterization of spherulites as a lipidic carrier for low and high molecular weight agents Pathways driving the endocytosis of mutant and wild-type EGFR in cancer.Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1.The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes.Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling Sigma-2 ligands induce tumour cell death by multiple signalling pathways.Characterization of pulmonary sigma receptors by radioligand binding Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.Sigma receptors [σRs]: biology in normal and diseased states Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents.Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.Synthesis and biological characterisation of 18F-SIG343 and 18F-SIG353, novel and high selectivity σ2 radiotracers, for tumour imaging properties.Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy.Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.Non-invasive molecular imaging for preclinical cancer therapeutic development.The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).Tactics for preclinical validation of receptor-binding radiotracers.Functional assays to define agonists and antagonists of the sigma-2 receptor.Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016).Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.2-Aminopyridine derivatives as potential σ(2) receptor antagonists.Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers

P2860

Q28468300-3BA0156C-FF94-4A6E-986D-7F6E4F105E6F Q30487033-949FE244-9648-40B3-BAE6-EF33C7FAB734 Q33589984-D74E815C-BF0D-48F7-AD89-DCD8295F1DFD Q33693048-B3DCFEE5-1D10-459C-8AFB-BE96516E0D0D Q33693052-1A82DE50-75B9-4071-863F-250BA7DCAFE7 Q33782364-9DA64D20-4C11-4777-B3FC-BE8012B68D41 Q33849311-D606C0C2-DF37-4EDF-ACED-579D509E894D Q34052669-58869B3F-506C-4613-AB56-9236C96025D9 Q34146404-05C98FDD-4A33-4CF9-A400-5FEA8C5D8076 Q34172682-5A1FBD7F-935D-451D-8FCF-7CABDACC17BC Q34197697-64D2E32D-669D-45BE-9AD9-4B4D91E29D07 Q34362333-A27E7E27-7E01-46CF-AC18-4D7E84B9A58D Q34665722-2B2FAEDC-10A2-446A-8222-549C23B8434B Q34781357-553AAAFE-233D-4B71-8FCB-4F54E72824B7 Q35000636-B800DC64-AF1D-4AFC-816B-18EA27FC664E Q35021013-A52A40C7-70A1-4EF6-B316-556D233F5A31 Q35234944-C7183C90-C2D2-44F4-B513-CBE2D46E186A Q35591598-3B5F1843-2877-470F-BCC9-9738BE220905 Q35652832-46283A45-B34F-4BE3-8C57-CDB22B089208 Q35879869-FA44B425-0C39-4759-9E7C-14433F14C486 Q35977409-8CDFB4C7-847B-4F72-86C7-FB347C286B64 Q36150331-57DFA700-6AE9-44AA-B858-4CA88489CC88 Q36249357-DBFFC5C0-B765-47FE-91A2-311D9A62C05C Q36551212-13DC1EF3-5462-484C-91AA-94CB8647CA1F Q37000551-1A59D3AF-C02A-49AC-A40A-47E296F099A5 Q37065888-70986B1E-262B-4B74-B051-A7D3B3FFAAD3 Q37150075-ADC4F2DA-7909-4C85-A647-D38519E65D47 Q37161130-1CE17F06-4217-4FAF-B332-64F558904902 Q37376094-E00BA594-D411-44CE-9458-B7487EFCD5CE Q37427252-BA521A21-BB2E-4A4C-9FC4-FC8F7C3D452F Q37777989-09BA4207-3305-4484-883F-C4E869A421BC Q38024011-AE8AEC1E-EA54-47EF-9863-BFB20D675313 Q38089102-ABA1FDFF-362B-40CC-B863-4E83CC3316D2 Q38166977-AC704DF8-9783-4DF6-B819-E0D514F6735A Q38984519-49D3F7CC-3CDF-4652-9142-10EF2EB9EDC4 Q39044023-7B9A5B7C-2B41-4917-8922-0124A89289CB Q39067013-B06369AF-B42B-4479-A722-D8C2C90362A3 Q39289664-40904A41-5626-4691-B02F-830062018E92 Q39297889-D2D18114-0BB2-4544-9D65-4F95396BF91F Q39377369-EEDC9B6E-CC06-4E9F-8031-3173311F7770

P2860

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.

http://www.wikidata.org/entity/Q35924939

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@ast

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@en

type

label

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@ast

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@en

prefLabel

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@ast

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@en

P1433

Q35924939-0E49DF0C-29F7-4115-B2A8-DEF1D53A5E63

P1476

Q35924939-51BCFE82-C1FD-41E3-82DC-F7896FA5D439

P2093

Q35924939-0E3C9202-9179-415A-975D-3AC65F40A1AA

Q35924939-43E31781-7424-47AB-AFC1-7D65AC7B4F51

Q35924939-5BEABDE6-F36D-4BE3-89A7-B54EB67961B6

Q35924939-6815D5B9-DF93-4A59-AD18-726F6015F82F

Q35924939-9B016C02-0B8F-49B9-B027-67040182CEF3

Q35924939-B3CC760B-8237-4F2F-BEC9-CEEB3878BED9

Q35924939-B789D164-6078-43AD-ACD7-9CE001DF0879

Q35924939-D4D65A33-49D9-4BBE-BC12-8890AE6027E6

Q35924939-E4475493-779C-4098-8992-0354D6A1689B

Q35924939-EC66842C-31A2-4A1E-9500-421E63ED068C

P2860

Q35924939-00AA6139-AD77-4314-BA94-75B59DCC92CB

Q35924939-0339F5C8-9608-4469-BD40-E5CD35977CF2

Q35924939-05A5ECD1-713E-4560-B9D9-ADEEC5A173C9

Q35924939-0B9E07F4-C1DF-4AA5-A2F9-7181850D9304

Q35924939-1219B332-6D85-43FA-AC64-C60E4707AEC5

Q35924939-1E680839-9D2D-4BB9-A97D-43E1CDAEA097

Q35924939-2080A94E-D869-4DC2-BD12-5861957C1DDF

Q35924939-319581FD-968A-4A18-896F-8EB0C56FD812

Q35924939-32C8042F-13D8-4E9C-BE28-C3E789625ADF

Q35924939-38A6502A-DBC3-47B9-8E8B-36C8472F6DFA

P2888

Q35924939-8DC437DC-05C5-465C-B0F3-3A790EB88EB7

P304

Q35924939-A5E7104A-5F7F-449D-9558-4C7C3F574E63

P31

Q35924939-64E59437-5311-432E-991B-0EAE318D0CF0

P356

Q35924939-5DFB9691-0CE8-4929-820C-8E3EC09F4C3D

P478

Q35924939-48CF3050-5D86-430E-835B-53FA9973DC21

P50

Q35924939-0B504356-7FD8-444A-AE56-6AAB90472344

P577

Q35924939-CD8D842D-72B9-4091-86D1-34E60A5779C3

P5875

Q35924939-B7743ACE-A1A6-4153-9745-C33A1CA104EE

P6179

Q35924939-63426CAE-A2A5-498F-8CE2-4CAE9D46B77A

P698

Q35924939-84FC761D-215A-4686-9034-5C57CA1F6A97

P921

Q35924939-E3AF4B8D-D58D-4391-A1C6-0903BBF8BCB0

P932

Q35924939-A47A5C37-267A-48E2-8331-FD145B6A56BE

P356

P1433

Molecular Cancer

P1476

Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.

@en

P2093

Fabian Johnston

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Kashiwagi

http://www.w3.org/2001/XMLSchema#string

Jinbin Xu

http://www.w3.org/2001/XMLSchema#string

Jonathan E McDunn

http://www.w3.org/2001/XMLSchema#string

Katherine Chang

http://www.w3.org/2001/XMLSchema#string

Kathryn Trinkaus

http://www.w3.org/2001/XMLSchema#string

Lynne Jones

http://www.w3.org/2001/XMLSchema#string

Peter O Simon

http://www.w3.org/2001/XMLSchema#string

Peter S Goedegebuure

http://www.w3.org/2001/XMLSchema#string

Robert H Mach

http://www.w3.org/2001/XMLSchema#string

P2860

Cell death: critical control points

Cancer statistics, 2007

In vivo protein transduction: delivery of a biologically active protein into the mouse

The role of Bcl-2 family members in non-small cell lung cancer.

BCL-2 in prostate cancer: a minireview.

TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells.

Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers

Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer.

Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.

Death receptors in chemotherapy and cancer.

P2888

P304

48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-6-48

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Richard S Hotchkiss

P577

2007-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6206084

http://www.w3.org/2001/XMLSchema#string

P6179

1030019276

http://www.w3.org/2001/XMLSchema#string

P698

17631687

http://www.w3.org/2001/XMLSchema#string

P921

P932

1939854

http://www.w3.org/2001/XMLSchema#string